News

Unified Community Action For A TB-Free Africa Kicks Off

Press Release:

The Africa Coalition on Tuberculosis (ACT!), whose inception was the result of a Declaration made in Washington, DC, USA in March 2012, kicked off activities at a week-long planning meeting in June in Tirano, Italy. Founding members of the coalition include tuberculosis (TB) advocates representing organizations in Zambia, Nigeria, Uganda, Kenya, Malawi, and Zimbabwe, with plans to expand and include all of Africa as the organization grows.

ACT!’s mission is to value and consolidate the power within communities throughout Africa to end the injustice of TB, a curable disease from which millions of our people suffer and die each year. ACT! will enable infected and affected communities to advocate for universal access to TB services by enhancing advocacy skills, knowledge tools and opportunities to contribute to and hold all stakeholders accountable for achieving a TB-free Africa.

Community advocates from Zambia, Nigeria, Zimbabwe, Malawi, Kenya and Uganda gathered in Tirano, Italy, from June 4-9, 2012, to develop the coalition strategic plan, which included inauguration of the leadership to enable kick off of regional TB activities.

The Coalition Task Force elected an Executive Committee that includes the President, Vice President, Secretary, Vice Secretary and Treasurer who will direct the affairs of the coalition for two years. This exercise commenced the regional one-year implementation of TB Advocacy in line with the mission and vision of the coalition and working towards achieving the global Stop TB targets.

This strategic planning meeting of the coalition was supported by the U.S. Agency for International Development, the Stop TB Partnership, RESULTS and PATH.

Albert Makone, Community Representative for the Working Group on New TB Drugs, is a member of ACT!.

For more information, please visit the ACT! Website at: http://www.aidsportal.org/web/acsm/africa-coalition-on-tb.

All correspondence to the Coalition can be emailed to: africotb@gmail.com.

More News
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...
22 Oct 2020
On Thursday, October 21st, 2020, the U.S. Centers for Disease Control and Prevention's (CDC) TB Trials Consortium (TBTC) announced results from their Phase 3, open-label trial: Study 31/A5349. The clinical trial identified a 4-month drug regimen composed of high-dose rifapentine, moxyifloxacin,...